A retrospective multicenter study of pegvisomant use in acromegaly within Russian Federation
Ожирение и метаболизмBACKGROUND: Acromegaly is a chronic neuroendocrine disorder, the prognosis of which depends on timely and adequate treatment. A high percentage of non-radical surgical treatment and the problem of resistance to first-line drug therapy necessitate the ...
E. G. Przhyalkovskaya +12 more
doaj +1 more source
Treatment update on acromegaly [PDF]
Einstein (São Paulo), 2004 Pegvisomant is a new drug that blocks growth hormone peripheralreceptors, allowing normalization of insulin-like growth factor-1levels and consequently of clinical symptoms, reducing morbidityand mortality associated with acromegaly in almost all ...
Tatiana Hotimsky Millner +1 more
doaj
Elevated intraocular pressure in patients with acromegaly [PDF]
, 2014 To evaluate central corneal thickness (CCT) and intraocular pressure (IOP) in a cohort of acromegalic patients, and to correlate CCT with serum levels of growth hormone (GH) and insulin-like growth factor 1 (IGF-1)
Floriani, Irene +7 more
core +1 more source
Diabetes Secondary to Acromegaly: Physiopathology, Clinical Features and Effects of Treatment
Frontiers in Endocrinology, 2018 Acromegaly is a rare disease due to chronic GH excess and to the consequent increase in IGF-1 levels. Both GH and IGF-1 play a role in intermediate metabolism affecting glucose homeostasis. Indeed, chronic GH excess impairs insulin sensitivity, increases
Francesco Ferraù +4 more
doaj +1 more source
Tumorgenezis és a szomatosztatin hatásmechanizmusának vizsgálata humán hipofízis adenomákban = Tumorigenesis and the effects of somatostatin in human pituitary adenomas [PDF]
, 2012 Protein western array módszerrel vizsgáltuk ép és tumoros hypophysis mintákból a fehérjeexpressziót. Humán hypophysis szövetben korábban nem ismert 116 fehérjét detektáltunk, továbbá a hypophysis tumogenezisében feltételezhetően szerepet játszó ...
Góth, Miklós +5 more
core
Pituitary gigantism: a case series from Hospital de San José (Bogotá, Colombia)
Archives of Endocrinology and MetabolismIntroduction Gigantism is a rare pediatric disease characterized by increased production of growth hormone (GH) before epiphyseal closure, that manifests clinically as tall stature, musculoskeletal abnormalities, and multiple comorbidities.
William Rojas García +2 more
doaj +1 more source
Pegvisomant-Induced Cholestatic Hepatitis in an Acromegalic Patient with UGT1A1 ⁎ 28 Mutation
Case Reports in Endocrinology, 2016 Pegvisomant (PEGv) is a growth hormone receptor antagonist approved for the treatment of acromegaly; one of its documented adverse effects is reversible elevation of hepatic enzymes.
Maria Susana Mallea-Gil +5 more
doaj +1 more source
Patients with Active Acromegaly are at High Risk of 25(OH)D Deficiency [PDF]
, 2015 Acromegaly is a chronic disease characterized by hypersecretion of growth hormone (GH) and insulin-like growth factor 1 (IGF-1). Electrolyte disturbances such as hypercalcemia and hyperphosphatemia are reported in patients with this disorder.
Aleksandra Jawiarczyk-Przybyłowska +2 more
core +2 more sources
Growth factor, energy and nutrient sensing signalling pathways in metabolic ageing [PDF]
, 2017 The field of the biology of ageing has received increasing attention from a biomedical point of view over the past decades. The main reason has been the realisation that increases in human population life expectancy are accompanied by late onset diseases.
Bettedi, L, Foukas, LC
core +1 more source